Extramammary Paget disease: a review
Clinical and Experimental Dermatology · 2026-08-28
DOI: 10.1093/ced/llag377 ↗Abstract
Abstract Extramammary Paget disease (EMPD) is an uncommon malignancy that affects areas rich in apocrine glands, such as genital and perianal skin. First described by Radcliffe Crocker in 1889, EMPD often remains confined to the epidermis for years, following a quiescent course. Diagnosis is frequently delayed or missed because of its insidious onset and nonspecific symptoms, which can mimic other inflammatory dermatoses. Importantly, EMPD is linked to underlying visceral malignancies, although the risk varies anatomically. Data from England on EMPD incidence and 5-year survival from 2013 to 2020 shows a crude incidence rate of 0.17 per 100 000 person-years. Additionally, the 5-year net survival for EMPD diagnosed in 2013 was 90.9%. The reported net survival for EMPD is comparable with melanoma (89.6%), prostate (85.8%) and breast cancers (85.9%) overall, i.e. for all stages combined. Management of EMPD focuses on identifying and addressing any associated underlying malignancies. Treatment options include surgery or topical treatments, and nonsurgical approaches such as radiotherapy and systemic treatment are used for advanced or metastatic disease. Treatment approaches may not be curative and recurrence rates can be very high, highlighting the importance of close surveillance. This review covers EMPD’s history, classification, epidemiology, aetiology, pathogenesis and diagnosis, and highlights current strategies for malignancy screening and patient management, thus contributing to our understanding of trends and outcomes for this rare disease.
EUVIMED